Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerJulia K Rotow, Philippe Gui, Wei Wu, et al.The Oncologist|December 10, 2024
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancerHoward J Lee, John Boscardin, Louise C Walter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2025
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung CancerJianxing He, Masahiro Tsuboi, Walter Weder, et al.The Journal of Clinical Investigation|May 17, 2022
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerShigeki Nanjo, Wei Wu, Niki Karachaliou, et al.Nature Genetics|November 7, 2017
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M Blakely, Thomas B K Watkins, Wei Wu, et al.Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.Cancer Discovery|July 27, 2022
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung CancerAshish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.Cell|August 22, 2020
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA SequencingAshley Maynard, Caroline E McCoach, Julia K Rotow, et al.Pageof 6